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Background: Few studies have evaluated the effectiveness of adalimumab in the real-life
setting in psoriatic arthritis (PsA).
Objective: To evaluate the 2-year retention rate of adalimumab in PsA patients. Potential
baseline parameters influencing persistence on treatment were also evaluated.
Methods: PsA patients from 16 Italian Rheumatology Units treated with adalimumab as
first- or second-line biological therapy were retrospectively evaluated. Adalimumab
retention rate was evaluated at 12 and 24 months. Logistic regression was used to
evaluate the association between predictor variables and adalimumab retention rate.
Results: From 424 patients (53.5% male, aged 48.3 ± 12.8 years) who started treatment
with adalimumab, 367 (86.6%) maintained treatment for 12 months and 313 (73.8%) for 2
years. At 24-months, Disease Activity in PsA (DAPSA) remission (defined as ≤4) and Low
Disease Activity (LDA) (≤14) were achieved in 22.8% and 44.4% of patients, respectively.
Adalimumab treatment significantly decreased the number of tender (7.0 ± 5.7 at baseline
vs. 2.3 ± 3.5 at 24 months, p < 0.001) and swollen joints (2.7 ± 2.8 at baseline vs. 0.4 ±in.org December 2019 | Volume 10 | Article 14971
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Frontiers in Pharmacology | www.frontiers0.9 at 24 months, p < 0.001), DAPSA (25.5 ± 10.9 at baseline vs. 11.0 ± 8.4 at 24months,
p < 0.001), PASI (5.3 ± 5.7 at baseline vs. 2.7 ± 2.8 at 24 months, p < 0.001) and CRP
(3.8 ± 6.3 at baseline vs. 1.2 ± 1.7 at 24 months, p < 0.001). Among a range of laboratory
and clinical variables, only female gender was associated with improved adalimumab
persistence at 24 months (OR: 1.98, 95% CI: 1.2–3.2, p = 0.005).
Conclusions: Independent of a range of predictor variables, adalimumab was shown to
be effective, while maintaining a high retention rate after 2 years in PsA patients.Keywords: psoriatic arthritis, biological drugs, adalimumab, retention rate, real-lifeINTRODUCTION
Psoriatic arthritis (PsA) is a chronic and invalidating disease
characterized by joint and entheseal inflammation affecting 0.05–
0.25% of the general population and 6–41% of patients with
psoriasis (Gottlieb and Dann, 2009; Laws et al., 2010; Olivieri
et al., 2014; Ogdie and Weiss, 2015).
Up until two decades ago, treatment of PsA was often
unsatisfactory. Findings based on the immunopathogenesis of
the disease have led to the development of biological drugs
directed against specific (pathogenetic) targets, in particular
tumor necrosis factor-a (TNFa). TNFa is a pleiotropic
cytokine which regulates several inflammatory reactions and
immune functions through the control of cellular processes
and plays a central role in the pathogenesis of PsA
(Mantravadi et al., 2017). Anti-TNFa drugs have opened new
therapeutic horizons in PsA, proving to be effective in the control
of the signs/symptoms of inflammation, in improving the quality
of life and the functional outcome, in inhibiting the progression
of the structural damage in the peripheral joints and presenting a
good safety profile (D'Angelo et al., 2012; Perrotta and Lubrano,
2016; D'Angelo et al., 2017). Treatment strategies of active,
predominantly peripheral PsA recommended by International
and National Guidelines suggest to use conventional disease-
modifying drugs anti-rheumatic (DMARDs), such as
methotrexate (MTX). In cases of inadequate response,
contraindication or intolerance to at least one DMARD,
treatment with biological drugs such as TNFa (adalimumab,
infliximab, etanercept, golimumab, or certolizumab pegol) or
anti-interleukin therapies (ustekinumab or secukinumab) should
be considered (Gossec et al., 2016; Marchesoni et al., 2017).
Adalimumab has been shown to be effective and reasonably
safe in reducing disease activity and controlling joint damage in
patients with PsA, even in comorbid conditions (D'Angelo et al.,
2012). However, despite its generally high efficacy, some patients
with PsA may be refractory to adalimumab therapy, may lose
response or develop drug intolerance over time (Perrotta and
Lubrano, 2016; D'Angelo et al., 2017). The persistence in therapy
in real-life clinical practice is increasingly recognised as a
surrogate marker for the efficacy and safety of a drug (Saad
et al., 2011). National registries provide clinical data from the
real-world setting, with the aim to monitor long-term safety of a
specific treatment, but they also yield other importantin.org 2information (difficult to achieve in clinical trials), such as drug
survival and long-term effectiveness (Armuzzi et al., 2014).
The present real-life study evaluated the persistence of
adalimumab in the management of PsA patients over a period
of 2 years. Potential baseline clinical and laboratory parameters
influencing persistence rate were also evaluated.METHODS
Patients and Study Design
The present retrospective non-interventional longitudinal study
included consecutive PsA patients who started a treatment with
adalimumab as of 1st January 2013 in 16 Italian Rheumatology
Centres. Inclusion criteria were the following: age ≥18 years;
diagnosed with active PsA and having started a treatment with
adalimumab in routine clinical practice, regardless of whether
they were biologic naïve or whether they had previously received
biologic treatment. Active PsA was defined by a rheumatologist
based on clinical judgment considered peripheral arthritis,
enthesitis or axial involvement. Diagnosis of PsA was clinical
(D'Angelo et al., 2016) and in addition, all patients satisfied
CASPAR (ClASsification criteria for Psoriatic ARthritis) criteria
for the classification of PsA (Taylor et al., 2006). Patients' written
consent were obtained according to the Declaration of Helsinki
when patients were first entered into the database for treatment.
Ethics committee approval from all participating centres and
written informed consent for the anonymous use of personal
data were obtained from every patient, in compliance with the
Italian Legislative Decree 196/2003.
All participating Centres have a recognised expertise in the
management of PsA and regularly collect data using a
standardized database on the efficacy and safety of patients
with PsA treated with biological drugs. For the purpose of this
study, the data extracted from the database were the following:
demographic features (age, sex, and time since PsA diagnosis),
clinical parameters (tender and swollen joints, dactylitis,
enthesitis assessed by physical examination according to the
expanded Leeds index, psoriasis according to Psoriasis Area
Severity Index [PASI], Disease Activity index for Psoriatic
Arthritis [DAPSA]) and treatment (previous biologics,
previous conventional DMARD, combined treatment, dose of
adalimumab) at the time of initiation and during the follow-up ofDecember 2019 | Volume 10 | Article 1497
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three time-points: baseline, 12 and 24 months.
Outcome Measures
Drug retention was retrospectively evaluated as the number of
patients (%) on treatment until definitive treatment interruption
over the study period. Reasons for discontinuation were analysed
and classified into the following categories: 1) lack of
effectiveness (including primary and secondary); 2) adverse
events (infection, skin or systemic reaction, and other adverse
events, including hematologic, pulmonary, renal, cardiovascular
complications, and malignancies, etc.); and 3) other reasons
(patient preference, change in hospital, desire for pregnancy,
disease remission, etc.). The effectiveness of adalimumab
treatment was also evaluated at 24 months and was defined as
the proportion of patients achieving remission, defined as a
DAPSA score ≤4 and low disease activity (LDA) as >4 and ≤14
(Gossec et al., 2016 and Schoels et al., 2016) .The effect of
adalimumab treatment on a range of clinical and laboratory
features and disease activity variables (tender and swollen joint
count, CRP, dactylitis, enthesitis, PASI and DAPSA) and extra-
articular manifestations (Crohn's disease, uveitis) was also
evaluated at 12 and 24 months.
Statistical Analysis
No formal power calculation was performed since this was a
retrospective longitudinal study that included consecutive PsA
patients seen in a real-life setting. Data are presented as mean ±
SDornumber and%.Comparisons invariables between twogroups
(i.e. patients discontinuing vs. those continuing adalimumab
treatment at 24 months) were performed by univariate analysis
using the Chi-squared test for categorical variables or the Mann-
Whitney U- Test for non-parametric continuous variables. Three
groups were compared (i.e. baseline, 12 and 24 months) by 1-way
ANOVA followed by Bonferroni post-hoc test to account for a-
inflation by type-1 error derived from multiple testing. Variables
that were found to be statistically significant predictors following
univariate analysiswere included inmultivariate regressionmodels.
A p-value of≤0.05was considered statistically significant. Statistical
analyses were performed using SPSS statistical software, version
20.0 (SPSS, Chicago, IL, USA).
RESULTS
Baseline Clinical Characteristics
A total of 424 PsA patients were included in the present study.
Baseline clinical characteristics are summarised in Table 1. The
majority of patients were male (N = 227, 53.5%) and mean age
was 48.3 ± 12.8 years. Three hundred and fifteen (74.3%) patients
had peripheral arthritis, 148 (47.3%) enthesitis, 87 (27.8%)
dactylitis, 81 (19.1%) axial involvement and 306 (72.5%) had
concomitant psoriasis. Extra-articular complications such as
uveitis (N = 27, 6.4%) and Crohn's disease (N = 23, 5.4%)
were less frequent. Frequent comorbid diseases at baseline
included hypertension (N = 130, 30.8%) and metabolic
syndrome (N = 75, 17.9%). The majority of patients presented
with moderately active disease, as observed by DAPSA scoreFrontiers in Pharmacology | www.frontiersin.org December 2019 | Volume 10 | Article 14973)
-
(25.5 ± 10.9). Prior to undertaking treatment with adalimumab,
291 (68.6%) patients were biologic naïve while almost all patients
received conventional DMARDs (N = 404, 95.3%). As regards
the 133 patients with a previous biologic treatment, 33 had
discontinued due to primary inefficacy, 64 due to secondary
inefficacy, 27 due to adverse events and 9 due to other reasons.
Adalimumab Treatment
Adalimumab was administered as monotherapy in 190 patients
(44.8%) and combined with MTX in 183 (43.2%) patients, the
majority (N = 164, 89.6%) receiving MTX 10-20 mg (mean dose
of 13.1 ± 3.0 mg) per week. Adalimumab was administered in
combination with DMARDs other than MTX including
sulfasalazine, leflunomide, cyclosporine and hydroxychloroquine
in 51 (12%) patients.
Effectiveness
The effect of adalimumab treatment was evaluated on some clinical
and laboratory measures (Figure 1). Both tender joint count (TJC)
and swollen joint count (SJC) were significantly decreased compared
to baseline values (TJC: 7.0 ±5.7 at baseline vs. 2.3 ±3.5 at 24months,TABLE 1 | Baseline clinical characteristics of psoriatic arthritis patients.
Clinical characteristics PsA (N = 424
General
Male patients, n (%) 227 (53.5)
Age (years) 48.3 ± 12.8
BMI (Kg/M2) 25.8 ± 4.4
Current smoker, n (%) 84 (19.8)
Disease duration from arthritis onset (years) 7.6 ± 7.2
Arthritis assessment
Arthritis, n (%) 315 (74.3)
Tender joint count 7.0 ± 5.7
Swollen joint count 2.7 ± 2.8
CRP (mg/dl) 3.8 ± 6.3
DAPSA 25.5 ± 10.9
Enthesitis, n (%) 148 (47.3)
Dactylitis, n (%) 87 (27.8)
Spondylitis, n (%) 81 (19.1)
Skin assessment
Current psoriasis, n (%) 306 (72.5)
PASI score 5.3 ± 5.7
Comorbidities, n (%)*
Hypertension 130 (30.8)
Metabolic syndrome 75 (17.9)
Depression 38 (9.2)
Hyperuricemia 32 (7.7)
Cardiovascular disease 28 (6.7)
Uveitis 27 (6.4)
Crohn's disease 23 (5.4)




Biologic naïve 291 (68.6)
Adalimumab
Monotherapy 190 (44.8)
plus methotrexate 183 (43.2)
plus other DMARD 51 (12.0)Data are presented as mean ± SD or number (%). BMI, body mass index; CRP, C-reactive
protein; DAPSA, disease activity in psoriatic arthritis; DMARD, disease-modifying anti
rheumatic drugs; PASI, psoriasis area severity index; PsA, psoriatic arthritis.*including
extra-articular manifestations.
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0.001) (Figures 1A,B). Similarly, PASI (5.3 ± 5.7 at baseline vs. 2.7 ±
2.8 at 24months, p<0.001) andCRP(3.8±6.3 at baseline vs. 1.2±1.7
at 24 months, p < 0.001) were significantly decreased in patients
treated with adalimumab over the 2-year period (Figures 1C, D).
MeanDAPSAscorewas significantlydecreasedcompared tobaseline
values after 12 and 24months (25.5 ± 10.9 at baseline vs. 11.0 ± 8.4 at
24 months, p < 0.001) of adalimumab treatment (Figure 2). Clinical
remission and LDA at 24months were achieved in 22.8% and 44.4%
of patients, respectively.
In addition, patients with enthesitis (47.3% at baseline vs.
15.1% at 24 months, p < 0.001) and dactylitis (27.8% at baseline
vs. 3.2% at 24 months, p < 0.001) were also significantly
decreased over the follow-up period.
Adalimumab Retention Rate and Factors
Influencing Retention at 24 Months
Of the 424 patients who started treatment with adalimumab, 367
(86.6%) maintained treatment for 12 months and 313 (73.8%)
for 24 months.
Univariate and multivariate analyses were used to examine
predictors of 24-month adalimumab persistence in PsA patients.
Considering all potential variables compared using univariateFrontiers in Pharmacology | www.frontiersin.org 4analyses (Table 2), only high baseline CRP levels (3.2 ± 5.3 mg/dl
discontinuing vs. 3.8 ± 6.3 mg/dl in adalimumab continuing
patients, p = 0.047) and female gender (34.2% in discontinuing
vs. 50.8% in adalimumab continuing patients, p = 0.004)
emerged as being significantly associated with improved
adalimumab persistence at 24 months. Stratification of patients
based on concomitant treatment (e.g. adalimumab monotherapy
vs. adalimumab plus MTX or adalimumab plus other DMARD)
did not reveal any significant difference in adalimumab retention
(p = 0.46) (Table 2). Furthermore, the presence of comorbid
diseases or exposure to previous biologic were not associated
with adalimumab retention. In a multivariate regression model
(including only gender and high baseline CRP levels), only female
sex emerged as a significant predictor of improved adalimumab
retention at 24 months (OR 1.98, 95% CI 1.2–3.2, p = 0.005).
Reasons for Adalimumab Discontinuation
Over the 24-month treatment period, adalimumab was
suspended in a total of 111/424 (26.2%) patients. Reasons for
discontinuation were primary inefficacy (N = 30, 7.1%),
secondary inefficacy (N = 15, 3.5%), adverse events (N = 26,
6.1%; subjective intolerance, allergic reaction, biliary colic,
diplopia, and paresthesia in limbs or other side effects) andFIGURE 1 | Effect of adalimumab treatment in PsA patients on tender [(A) N = 303, 271, 275 at 0, 12, and 24 months] and swollen joints [(B) N = 303, 271, 275 at
0, 12, and 24 months], CRP [(C) N = 298, 269, 272 at 0, 12, and 24 months] and PASI score [(D) N = 99, 73, 39 at 0, 12, and 24 months]. CRP, C-reactive
protein; PASI, psoriasis area severity index; SJC, swollen joint count; TJC, tender joint count. Data presented as mean ± SD. Asterisks denote statistically significant
differences compared to baseline values after 1-way ANOVA followed by Bonferroni post-hoc test.December 2019 | Volume 10 | Article 1497
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paternity leave, not reported, or not recorded).DISCUSSION
Efficacy and safety data currently available for anti-TNFa drugs for
the treatment of PsA are mainly derived from randomised clinical
trials (RCTs). Although RCTs still represent the most powerful
research tool to confirm the efficacyof a treatment, results emerging
from these studies are based on a selected population, with the
exclusion of co-morbidities, treated and observed for a limited
period of time. In routine clinical practice (real life), the decision to
choose a specific biologic needs to take into consideration that
patients may often be affected by multiple comorbidities, receive
concomitant medication, and necessitate treatment for a greater
duration, characteristics that are profoundly different from a RCT.
It is increasingly recognised that the persistence in treatment is a
good surrogate of both effectiveness (efficacy in the real-life setting)
and tolerability of a drug (Saad et al., 2011).
The short- and long-term benefit of adalimumab for the
treatment of PsA is already documented from several clinical
trials and meta-analyses (Gladman et al., 2007; Mease et al., 2009;
Burmester et al., 2013). However, little evidence is available on
the persistence and effectiveness of adalimumab administered as
first- or second-line biologic treatment in the real-life setting.
Theresults fromthisreal-life study indicate thatadalimumabcanbe
considered as a therapeutic option for the long-term treatment in PsA
patients, regardless of their prior exposure to biologics orDMARDs or
the presence of comorbid diseases. The majority of patients (86.6%)
retained treatmentwith adalimumab for up to 1 yearwith only a slight
reduction observed at 2 years (73.8% persistence), corroborating with
findings from European registry studies (70–88%) for 1 year
persistence rates (Heiberg et al., 2008; Saad et al., 2009; Glintborg
et al., 2011; Aaltonen et al., 2017; Stober et al., 2018). However, ourFrontiers in Pharmacology | www.frontiersin.org 5results showedhigher rates than another real-life registry performed in
Italy, with 2-year retention rate of 48% in PsA patients treated with
golimumab (Manara et al., 2017). Furthermore, in that study, no
differencewasobserved in retention ratebetweenfirst- and second-line
treatment in patients with rheumatoid arthritis or PsA (Manara et al.,
2017). Although clinical characteristics and disease severity of patients
treated in our studywere similar to European registries, it is important
to note that 68.6% were naïve to biologics and 55.2% were receiving
concomitant DMARDs (43.2% in combination with MTX). These
features may favour drug response and persistence, since evidence
suggests that response to adalimumab is lower after previous TNF
inhibitor (Merola et al., 2017) and concomitant MTX can improve
anti-TNF drug survival (Glintborg et al., 2011), although other studies
dispute the benefit of combineduse ofDMARDs and anti-TNFagents
on drug survival (Mease et al., 2015; Aaltonen et al., 2017). In addition,
wedidnotobserveanyadvantage indrugpersistence inpatients treated
with adalimumab asmonotherapy compared to those receivingMTX
and/or other DMARDs. Recently, a retrospective single-centre cohort
study based in the UK was performed in patients with PsA who
initiated anti-TNF therapy (adalimumab in 42%of cases) (Stober et al.,
2018). Retention rateswere similar to those observed in our study at 12
(79%) and 24 months (73%). Interestingly, the presence of metabolic
syndrome and female sex were identified as predictors of lower drug
persistence (Stober et al., 2018), findings that have been reported by
other groups (Heiberg et al., 2008; Glintborg et al., 2011), but have not
been confirmed by our study. The small number of patients with
metabolic syndrome and BMI value ≥30 in our cohort might account
for the lack of association between obesity and worse adalimumab
performance. Why female sex emerged as a predictor of better
adalimumab survival rate does not seem to have a logical
explanation, although this has also been observed in psoriasis
patients (Verma et al., 2018). However, published data on this topic
are based on study populations of PsA patients taking any TNF
inhibitors and do not investigate drugs individually. Differences in
patient characteristics across studies such as age, baseline disease
severity and the presence of underlying fibromyalgia may also play a
role in gender related differences in drug persistence. Further studies
well help to clarify this result in more detail.
HighlevelsofCRPatbaselinealsopredicted improvedadalimumab
persistence at 24 months in our hands, a finding that has also been
observedpreviously inankylosing spondylitis (Glintborget al., 2010) as
well as PsApatients (Glintborg et al., 2011; Aaltonen et al., 2017).High
CRP levels at baseline are associated with systemic inflammation and,
therefore, may help identify patients with more active disease who are
more likely to benefit from adalimumab treatment than patients with
less inflammatory active disease.
Given the lack of association observed in our analysis between
a range of laboratory and clinical variables with persistence rate,
adalimumab may be considered as a viable therapeutic option in
a heterogeneous population of patients in the real-world PsA
setting, without the need to restrict treatment to specific
subgroups or special patient populations.
Highpersistence ratewasparalleledwith amarked improvement
in arthritis measures such as TJC, SJC, DAPSA, enthesitis, and
dactylitis. PASI and CRP were also significantly improved as early
as 12 months and remained stable up to 2 years. We also observedFIGURE 2 | Effect of adalimumab treatment in PsA patients on DAPSA (N =
209, 183, 189 at 0, 12 and 24 months). DAPSA, disease activity in psoriatic
arthritis. Data are presented as mean ± SD. Asterisks denote statistically
significant differences compared to baseline values after 1-way ANOVA
followed by Bonferroni post-hoc test.December 2019 | Volume 10 | Article 1497
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PsA patients who discontinued treatment with adalimumab
after 2 years, only 6.1%were actually due to adverse events.
LIMITATIONS
While the main strength of the present study lies in the large
sample size (N = 424) and 2-year follow-up period, subgroup
analysis for some specific clinical (e.g. tender and swollen joint
count, PASI and DAPSA) and laboratory measures (e.g. CRP)
were hampered by missing data for some patients. The
retrospective design was another limitation. However, as this
study involved 16 rheumatological centres, evaluating the real-
life use of adalimumab as first or second-line treatment in
biologic naïve or previous biologic failure in the PsA setting,
results can be generalised to the larger Italian territory.
CONCLUSION
In this large real-life cohort, the use of adalimumab was found to
be highly effective in PsA patients. High retention was achievedFrontiers in Pharmacology | www.frontiersin.org 6at 1 (86.6%) and 2 years (73.8%) and given the lack of association
between several laboratory and clinical variables with persistence
rate, adalimumab may be considered as a viable therapeutic
option in a heterogeneous population of patients in the real-
world PsA setting.DATA AVAILABILITY STATEMENT
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Clinical characteristics Adalimumab treatment P-value
Discontinuing (N = 111) Continuing (N = 313)
General
Female patients, n (%) 38 (34.2) 159 (50.8) 0.004
Age (years) 47.9 ± 13.1 48.4 ± 12.7 0.69
BMI (Kg/M2) 25.4 ± 4.5 25.9 ± 4.3 0.19
Current smoker, n (%) 24 (27) 60 (20.5) 0.26
Arthritis assessment
Tender joint count 7.3 ± 6 7 ± 5.7 0.93
Swollen joint count 2.6 ± 2.8 2.7 ± 2.8 0.71
CRP (mg/dl) 3.2 ± 5.3 3.8 ± 6.3 0.047
DAPSA 24.7 ± 9.8 25.5 ± 10.9 0.61
Enthesitis 54 (48.6) 148 (47.3) 0.89
Dactylitis 21 (19.1) 87 (27.8) 0.09
Skin assessment
PASI 4.4 ± 4.3 5.3 ± 5.7 0.63
Comorbidities*, n (%)
Hypertension 31 (28.2) 99 (31.7) 0.57
Metabolic syndrome 19 (17.6) 56 (17.9) 1.0
Depression 12 (11.1) 26 (8.5) 0.53
Hyperuricemia 4 (3.7) 28 (9.1) 0.12
Cardiovascular disease 7 (6.5) 21 (6.8) 1.0
Uveitis 7 (6.4) 20 (6.4) 1.0
Crohn's disease 4 (3.6) 19 (6.1) 0.47
Ulcerative colitis 3 (2.7) 9 (2.9) 1.0
Medication, n (%)
Biologic naïve 74 (66.7) 217 (69.3) 0.69
Adalimumab
Monotherapy 48 (43.2) 142 (45.4) 0.46
Plus methotrexate 46 (41.4) 137 (43.8)
Plus other DMARD 17 (15.3) 34 (10.9)December 2019 | Volume 10 | ArtData are presented as mean ± SD or number (%). N refers to number of patients treated with adalimumab for 24 months. BMI, body mass index; CRP, C-reactive protein; DAPSA, disease
activity in psoriatic arthritis; DMARD, disease-modifying anti-rheumatic drugs; PASI, psoriasis area severity index; PsA, psoriatic arthritis.*including extra-articular manifestations. Com-
parisons in variables between patients discontinuing vs. those continuing adalimumab treatment at 24 months were performed using the Chi-squared test for categorical variables or the
Mann-Whitney U-Test for non-parametric continuous variables. P-values reporting statistically significant differences are highlighted in bold.icle 1497
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